Status:
UNKNOWN
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
Lead Sponsor:
China Medical University Hospital
Conditions:
Aneurysmal Subarachnoid Hemorrhage
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
PHASE3
Brief Summary
This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
Detailed Description
Astragalus membranaceus (AM, Huang-Chi) is a Chinese herb used extensively in China as a traditional treatment to treat stroke for a long time, and a number of studies have shown that AM can reduce ce...
Eligibility Criteria
Inclusion
- Patients who admitted to the hospital within 24 hours of onset of aneurysmal subarachnoid hemorrhage (SAH) stroke
- Subarachnoid hemorrhage documented on head CT
- Hunt Hess Grade 1-4
- Both Male and Female
- Age more than 20 and less than 80 years older
- Informed consent obtained from a patient or legal representative before enrollment
Exclusion
- Traumatic or mycotic aneurysms
- Complication of serious heart or hepatic disease or infection or renal failure
- Malignant tumor
- Patients judged to be inappropriate by physician in charge
- Pregnant / breast feeding women
- Patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening
- Ever stroke, and mRS≧3
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03271697
Start Date
September 1 2017
End Date
September 1 2020
Last Update
September 5 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.